Shukokai Medical Corporation
Basic information
- Head office
- Chief executive
- Capital
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- 1958-01-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| GICC | ||||||||
| HASUMI免疫クリニック | ||||||||
| Hasumi International Research Foundation | ||||||||
| ICVS東京クリニック | ||||||||
| エアランゲン大学 | ||||||||
| オーストリア・アカデミー・オブ・サイエンス | ||||||||
| ニューヨーク科学アカデミー | ||||||||
| プレーヴェン大学 | ||||||||
| マレーシア国民大学付属病院 | ||||||||
| メリーランド大学 | ||||||||
| 中国医学科学院癌研究所 | ||||||||
| 中国長春中医学院 | ||||||||
| 介護老人保健施設聖の郷 | ||||||||
| 北京中医薬大学 | ||||||||
| 北京珠光会 | ||||||||
| 北京珠光会医薬品開発有限公司 | ||||||||
| 医療法人社団ICVS | ||||||||
|
|
||||||||
| 吉林省腫瘍医院 | ||||||||
|
|
||||||||
|
|
||||||||
| 珠光会インターナショナル | ||||||||
| 米国トーマス・ジェファーソン大学 | ||||||||
| 米国メリーランド大学 | ||||||||
| 米国国立癌研究所 | ||||||||
| 米国法人蓮見国際研究財団 | ||||||||
| 聖ヶ丘病院 | ||||||||
| 英国王立医学会 | ||||||||
| 英屬開曼群島商雅智有限公司台灣分公司 | ||||||||
| 蓝莲(杭州)生物科技有限公司 | ||||||||
| 蓮見再生医療研究所 | ||||||||
| 蓮見国際研究財団ブルガリア | ||||||||
| 蓮見癌研究所 |
Network
History
Began an experiment on cancer prevention using the Hasumi Vaccine in Heguri Village, Nara Prefecture![]()
Since 1988, under the current leadership, efforts have focused on developing cancer antigen libraries for each type of cancer and expanding the range of cancers for which Hasumi Vaccine can be used.![]()
Established the U.S. corporation Hasumi International Research Foundation and developed a framework for cancer research![]()
Established Shukokai International in the United States and strengthened the framework for overseas research on the Hasumi Vaccine![]()
Began clinical research on the Hasumi Vaccine with the FIOCRUZ Institute of Brazil's Ministry of Health and the Fortaleza Claude Bernard Institute in Brazil![]()
Established S.I.J. Co., Ltd. and established a cooperative relationship with the U.S. corporation Shukokai International![]()
In 1999, the Hasumi International Research Foundation was established in the United States. By deepening ties with researchers around the world, it conducts research and development on advanced cancer immunotherapies and their clinical applications.![]()
In 1999, a dendritic cell vaccine was developed through joint research with Thomas Jefferson University.![]()
In 2000, the bioactivity of Hasumi Vaccine was demonstrated through joint research with the University of Maryland.![]()
Introduced self-managed medical records at the Shukokai Clinic and promoted awareness of the importance of self-management of cancer![]()
Demonstrated the adjuvant activity of the Hasumi Vaccine at the University of Maryland in the United States![]()
The Hasumi Cancer Research Institute developed the anti-cancer herbal medicine Immuno Hasumi and began clinical application (in cooperation with Saitama Medical University and Changchun University of Chinese Medicine, China).![]()
The Hasumi DC & AT vaccine was jointly developed with Thomas Jefferson University in the United States, and clinical trials began.![]()
Supported the first lecture hosted by the NPO Immunotherapy Roundtable, “Mechanisms of Cancer Recognition and Elimination,” featuring invited speaker Hiroyuki Itsuki (held in Osaka).![]()
Supported the first International Cancer Vaccine Symposium (held in Tokyo), hosted by the Hasumi International Research Foundation, which was attended by many internationally active researchers.![]()
Kenichiro Hasumi, Chairman of the Board, delivered an invited lecture at the 10th international conference “AIDS, Cancer and Related Problems” (held in St. Petersburg, Russia).![]()
The cancer vaccine book “Zero In On the Cancer Cell” was published by the U.S. corporation Hasumi International Research Foundation.![]()
Beijing Juhokai Pharmaceutical Development Co., Ltd. was established and partnered with Beijing University of Chinese Medicine.![]()
The 3rd International Cancer Vaccine Symposium (held in London) was jointly hosted by the U.S. corporation Hasumi International Research Foundation and the Royal Society of Medicine.![]()
In 2005, a prototype HITV (Human Initiated Therapeutic Vaccine) therapy was successfully developed as a “therapeutic vaccine” combining conventional treatments such as radiation therapy and chemotherapy with cell therapy using dendritic cells.![]()
“Fighting Cancer with the Power of Immunity” was published by the U.S. corporation Hasumi International Research Foundation.![]()
The 4th International Cancer Vaccine Symposium (held in Washington, D.C.) was jointly hosted by the U.S. corporation Hasumi International Research Foundation and the U.S. National Cancer Institute.![]()
The first Tokyo lecture was held at the Tokyo Otemachi Sankei Plaza Hall, and has been held annually since then.![]()
The 5th International Cancer Vaccine Symposium (in Vienna) was held in collaboration with the U.S. corporation Renmei International Research Foundation and the Austrian Academy of Sciences.![]()
Published by the U.S. corporation Renmei International Research Foundation: 'Cancer Vaccine of Love from a Determined Doctor to a Determined Patient Until the End.'![]()
Opened the ICVS Tokyo Clinic, affiliated with the U.S. corporation Renmei International Research Foundation, as a dendritic cell therapy specialty facility.![]()
Chairman Renmei delivered an invited lecture at Murni Teghu Memorial Hospital, established in Medan, Indonesia, under the theme 'Future Cancer Treatment - New Concept and Modality.'![]()
In 2013, the research facility was relocated from Chofu to Asagaya, and an even more extensive research system was established.![]()
In 2013, development advanced on an “acne vaccine” intended to use the power of the immune system to eliminate acne bacteria, one of the causes of acne. The vaccine uses artificially synthesized antigen peptides based on membrane proteins of acne bacteria and has been patented in countries around the world.![]()
To unify the flow from cancer prevention to treatment, the Jukou Clinic was relocated and integrated into BSL-48 Clinic; the corporate headquarters office and Renmei Cancer Research Institute were also relocated.![]()
Following the research and clinical achievements of cancer vaccines by the late Dr. Kiichiro Renmei, which received high acclaim, the first Japanese physician in the history of American medical universities was awarded a professorship at Thomas Jefferson University in the United States, bearing the name 'Renmei.'![]()
In 2015, to comply with the Act on the Safety of Regenerative Medicine, an application was filed to register the clean room at the research institute as a cell culture and processing facility. Following an on-site inspection by the Pharmaceuticals and Medical Devices Agency (PMDA), authorization was obtained to manufacture specified processed cells (facility number: FA3150018).![]()
Topic: “A Medical Roadmap to Avoid Getting Lost in Cancer Treatment” Speaker: Kenichiro Hasumi, Chairman of the Hasumi International Research Foundation, a U.S. corporation![]()
Topic: “Immunotherapy’s Evolution—What Is Happening Now at the Front Lines of Cancer Treatment, and What Will Happen Next?” Speaker: Kenichiro Hasumi, Chairman of the Hasumi International Research Foundation, a U.S. corporation![]()
BSL-48 Clinic relocated to Asagaya and was renamed BSL-48 Jukou Clinic. K-101 Clinic was renamed BSL-48 International Clinic and moved to the former BSL-48 Clinic location.![]()
News
There is no news.